Core Viewpoint - The company, Innovent Biologics, reported significant financial growth for the six months ending June 30, 2025, with a 50.6% increase in revenue and a return to profitability, driven by strong performance in its oncology product line and expansion of its product offerings [1][2]. Financial Performance - Revenue from customer contracts reached RMB 5.953 billion, a year-on-year increase of 50.6% [1] - The company achieved a profit of RMB 834 million, marking a turnaround from previous losses [1] - Basic earnings per share were reported at RMB 0.51 [1] - Non-IFRS profit rose to RMB 1.213 billion, indicating improved operational efficiency [1] Product Performance - Product revenue totaled RMB 5.234 billion, reflecting a year-on-year growth of 37.3% [1] - The oncology product portfolio maintained a leading advantage, with strong performance from major products and continuous contributions from new product revenues [1] - The product portfolio has expanded to 16 products, with five new drugs successfully commercialized during the reporting period [2]
港股异动 | 信达生物(01801)绩后高开逾4% 上半年利润8.34亿元 肿瘤产品组合领先优势稳固